Volume 122, Issue s36 pp. 41-45
Full Access

Cyclosporin A in atopic dermatitis

J.S. ROSS

J.S. ROSS

St John's Hospital for Diseases of the Skin and St Thomas's Hospital, London, U.K.

Search for more papers by this author
R.D.R. CAMP

Corresponding Author

R.D.R. CAMP

St John's Hospital for Diseases of the Skin and St Thomas's Hospital, London, U.K.

Dr R.Camp, Institute of Dermatology, St Thomas's Hospital, Lambeth Palace Road, London SEI 7EH, U.K.Search for more papers by this author
First published: June 1990
Citations: 29

SUMMARY

Over the past 10 years, oral cyclosporin A (CyA) has been used to treat a range of inflammatory and immunologically mediated dermatological conditions, but only psoriasis has been shown to be responsive in double-blind, controlled trials. Thirteen patients with severe atopic dermatitis were treated for up to 31 months. Ten patients had a good response, one patient a moderate response and two a slight response. In two of these patients, CyA was withdrawn after more than 2 years of continuous treatment because of increasing plasma creatinine levels. Cyclosporin A appears to be useful in the treatment of severe, therapy-resistant atopic dermatitis, but careful monitoring of side-effects and dose adjustments are required.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.